Information  X 
Enter a valid email address

Verona Pharma PLC Ord 5P (VRP)

Date Time Source Announcement
31 Mar 2020 7:00 am
GNW
Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD
20 Mar 2020 11:28 am
GNW
Verona Pharma plc: Issue of Equity and Total Voting Rights
17 Mar 2020 2:06 pm
RNS
Second Price Monitoring Extn
  2:01 pm
RNS
Price Monitoring Extension
16 Mar 2020 5:13 pm
GNW
2019 Annual Report and Accounts and Notice of AGM
05 Mar 2020 4:01 pm
GNW
Grant of Restricted Stock Units and PDMR Dealings
27 Feb 2020 7:00 am
GNW
Verona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update
21 Feb 2020 7:00 am
GNW
Verona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update
14 Feb 2020 7:00 am
GNW
Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research
07 Feb 2020 7:00 am
GNW
Holding(s) in Company TR-1: Standard form for notification of major holdings
28 Jan 2020 7:00 am
GNW
Verona Pharma to Present at LSX World Congress 2020
17 Jan 2020 1:06 pm
GNW
Holding(s) in Company TR-1: Standard form for notification of major holdings
13 Jan 2020 4:41 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
  5:00 am
GNW
Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy
10 Jan 2020 11:00 pm
GNW
Verona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy
07 Jan 2020 7:00 am
GNW
Verona Pharma Appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor Relations
28 Nov 2019 10:25 am
GNW
Holding(s) in Company TR-1: Standard form for notification of major holdings
27 Nov 2019 7:00 am
GNW
Verona Pharma plc: Grant of Options to PDMR
18 Nov 2019 7:00 am
GNW
Verona Pharma plc: PDMR Dealing – Purchase by Chairman
14 Nov 2019 7:00 am
GNW
Verona Pharma plc: PDMR Dealing – Purchase by Chairman
13 Nov 2019 7:00 am
GNW
Verona Pharma to Present at Jefferies 2019 London Healthcare Conference
11 Nov 2019 7:00 am
GNW
Verona Pharma to Participate in Two Upcoming Institutional Investor Conferences in New York
05 Nov 2019 7:00 am
GNW
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2019
29 Oct 2019 7:00 am
GNW
Verona Pharma to Announce Financial Results for the Three and Nine Months Ended September 30, 2019 and Provide Clinical Development Update
17 Oct 2019 7:00 am
GNW
Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD
15 Oct 2019 7:00 am
GNW
Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019
19 Sep 2019 7:00 am
GNW
Verona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019
09 Sep 2019 2:33 pm
GNW
Holding(s) in Company TR-1: Standard form for notification of major holdings
09 Aug 2019 9:35 am
GNW
Verona Pharma plc: PDMR Dealing
06 Aug 2019 7:00 am
GNW
Verona Pharma plc: Operational Update and Financial Results for the Three and Six Months Ended June 30, 2019
05 Aug 2019 7:00 am
GNW
Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD
30 Jul 2019 7:00 am
GNW
Verona Pharma to Announce Financial Results for Second Quarter Ended June 30, 2019 and Provide Clinical Development Update
24 Jul 2019 7:00 am
GNW
Verona Pharma to Attend BTIG Biotechnology Conference 2019 and Present at 2019 Wedbush PacGrow Healthcare Conference
25 Jun 2019 7:00 am
GNW
Verona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of Ensifentrine
04 Jun 2019 7:00 am
GNW
Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD
30 May 2019 7:00 am
GNW
Verona Pharma to Present at Jefferies 2019 Global Healthcare Conference
29 May 2019 11:07 am
RNS
PDMR Dealing
20 May 2019 3:15 pm
GNW
Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
07 May 2019 12:51 pm
GNW
Result of AGM
  7:00 am
GNW
Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials
  7:00 am
GNW
Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019
02 May 2019 12:00 pm
GNW
Verona Pharma to Present Clinical Trial Data of Ensifentrine for COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
01 May 2019 7:00 am
GNW
Verona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development Update
  7:00 am
GNW
Verona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK Broker
25 Apr 2019 12:07 pm
GNW
Verona Pharma to Host Investor & Analyst R&D Forum in London on May 8, 2019
09 Apr 2019 7:00 am
GNW
Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate Ensifentrine
04 Apr 2019 7:00 am
GNW
Grant of Options and RSUs and PDMR Dealings
26 Mar 2019 7:00 am
GNW
Verona Pharma to Present at H.C. Wainwright Global Life Sciences Conference
25 Mar 2019 7:00 am
GNW
PDMR Dealing
22 Mar 2019 4:00 pm
GNW
2018 Annual Report and Accounts and Notice of AGM 
21 Mar 2019 7:00 am
GNW
Dr. Martin Edwards Joins Verona Pharma as Non-Executive Director
20 Mar 2019 7:00 am
GNW
PDMR Dealing
11 Mar 2019 9:48 am
GNW
PDMR Dealing
07 Mar 2019 8:14 am
GNW
PDMR Dealing
05 Mar 2019 9:48 am
GNW
PDMR Dealing
04 Mar 2019 7:00 am
GNW
Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD
28 Feb 2019 7:00 am
GNW
Verona Pharma to Present at Cowen and Company 39th Annual Health Care Conference
26 Feb 2019 7:00 am
GNW
Verona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development Update
20 Feb 2019 7:00 am
GNW
Verona Pharma to Announce Financial Results for Full Year ended December 31, 2018 and Provide Clinical Development Update
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t